Pfizer Reports Phase 3 Data for Venetoclax in HIV

Pfizer today announced Phase 3 results for venetoclax in patients with HIV. The study demonstrated that venetoclax reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of HIV and support the continued development of venetoclax in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.